Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
6.96
-0.26 (-3.60%)
At close: Oct 5, 2026, 4:00 PM EDT
6.95
-0.01 (-0.14%)
After-hours: Oct 5, 2026, 7:30 PM EDT
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
47.20M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 34.59M |
| Celularity | 18.97M |
| Apollomics | 8.84M |
| ImageneBio | 800.00K |
| CervoMed | 331.30K |
| Serina Therapeutics | 130.00K |
| Impact BioMedical | 35.00K |
TIL News
- 7 weeks ago - Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - Instil Bio downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 9 months ago - Baird downgrades Instil Bio on discontinuation of AXN-2510 - TheFly
- 9 months ago - Instil Bio downgraded to Neutral from Outperform at Baird - TheFly
- 9 months ago - Instil Bio’s Axion discontinues clinical development of AXN-2510 - TheFly
- 9 months ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire